Substituted piperidines as soluble epdxide hydrolase inhibitors
AssigneeThe Regents of the University of California
InventorsBruce D. Hammock, Kin Sing Lee, Bora Inceoglu, Karen Wagner
Life of this patent
Estimating the term…
Abstract
Provided are methods for treating, reducing, alleviating, and/or inhibiting neuropathic pain by orally, intravenously or intrathecally administering an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”), to a patient in need thereof. The neuropathic pain treated is selected from the group consisting of post-herpetic neuralgia, trigeminal neuralgia, focal peripheral nerve injury, and anesthesia dolorosa, central pain due to stroke or mass lesion, spinal cord injury, or multiple sclerosis, and peripheral neuropathy due to diabetes, HIV, or chemotherapy.
Claims8
A method of inhibiting a soluble epoxide hydrolase in a subject, said method comprising administering to said subject a compound selected from the group consisting of:
- (S)-1-(1-(2-methylbutanoyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea;
- and
- 1-(1-(butylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea,
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.